Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Andrew B. Lassman(Columbia University), Patrick Roth(University Hospital of Zurich), Pierre Giglio(Medical University of South Carolina), Patrick Y. Wen(Dana-Farber Cancer Institute), Cristóbal Belda-Iniesta(Instituto de Salud Carlos III), Steven Rowsey(Rapt Therapeutics (United States)), Jeffrey J. Raizer(Northwestern University), Filip De Vos(University Medical Center Utrecht), Miguel Gil‐Gil(GEICAM – Spanish Breast Cancer Group), Vinay K. Puduvalli(The University of Texas MD Anderson Cancer Center), Harris S. Soifer(Kura Oncology (United States)), Francesca Avogadri(Rapt Therapeutics (United States)), Timothy F. Cloughesy(University of California, Los Angeles), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre), Susan Moran(QED Technologies (United States)), Nicholas Butowski(University of California, San Francisco), Cindy Xu(Rapt Therapeutics (United States)), Paul M. Clément(Universitair Ziekenhuis Leuven), Morris D. Groves(Texas Oncology), Wei Ge(People's Liberation Army No. 150 Hospital)
Cited by 76
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k